[go: up one dir, main page]

NO953832L - Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa - Google Patents

Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa

Info

Publication number
NO953832L
NO953832L NO953832A NO953832A NO953832L NO 953832 L NO953832 L NO 953832L NO 953832 A NO953832 A NO 953832A NO 953832 A NO953832 A NO 953832A NO 953832 L NO953832 L NO 953832L
Authority
NO
Norway
Prior art keywords
cyclic compounds
platelet
glycoprotein iib
iiia
inhibitors
Prior art date
Application number
NO953832A
Other languages
English (en)
Other versions
NO953832D0 (no
Inventor
William Frank Degrado
Sharon Anne Jackson
Shaker Ahmed Mousa
Anju Parthasarathy
Michael Sworin
Maria Rafalski
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of NO953832D0 publication Critical patent/NO953832D0/no
Publication of NO953832L publication Critical patent/NO953832L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Denne oppfinnelsen vedrører nye, sykliske forbindelser som inneholder karbosykliske ringsystemer, som kan anvendes som antagonister for blod- plateglykoprotein Ilb/IIIa-komplekset, farmasøytiske preparater som inneholder slike sykliske forbindelser sammen med eller uten andre terapeutiske midler, og fremgangsmåter for anvendelse av disse forbindelsene sammen med eller uten andre terapeutiske midler, for inhiberingen av blodplateaggregasjon, som trombolytika og/eller for behand- ling av andre tromboemboliske sykdom- mer. Denne oppfinnelsen vedrører også fremgangsmåter for anvendelse av de sykliske forbindelsene ifølge oppfin- nelsen i kombinasjon med antikoagula- sjonsmidler, slik som warfarin eller heparin, eller ytterligere anti- blodplatemidler, slik som aspirin, piroxicam eller ticlopidin, eller trom- bininhibitorer, slik som borpeptider, hirudin eller argatroban, eller trom- bolytiske midler, slik som vevsplas- minogenaktivator, anistreplase, urokin- ase eller streptokinase, eller kombina- sjoner derav, til behandlingen av trom- boemboliske sykdommer.
NO953832A 1993-03-29 1995-09-28 Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa NO953832L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3844893A 1993-03-29 1993-03-29
PCT/US1994/003223 WO1994022910A1 (en) 1993-03-29 1994-03-28 CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa

Publications (2)

Publication Number Publication Date
NO953832D0 NO953832D0 (no) 1995-09-28
NO953832L true NO953832L (no) 1995-11-28

Family

ID=21900014

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953832A NO953832L (no) 1993-03-29 1995-09-28 Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa

Country Status (10)

Country Link
EP (1) EP0691987A1 (no)
JP (1) JPH08508498A (no)
AU (1) AU6415894A (no)
CA (1) CA2159070A1 (no)
FI (1) FI954556A (no)
HU (1) HUT72896A (no)
NO (1) NO953832L (no)
NZ (1) NZ263456A (no)
PL (1) PL310896A1 (no)
WO (1) WO1994022910A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2159072A1 (en) * 1993-03-29 1994-10-13 Lin-Hua Zhang Novel processes and intermediate compounds for the preparation of platelet glycoprotein iib/iiia inhibitors
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
CA2272317C (en) * 1996-11-27 2001-01-30 Rhone-Poulenc Rorer Pharmaceuticals Inc. Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound
US6010911A (en) * 1997-04-30 2000-01-04 Medtronic, Inc. Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
BR112012011731A2 (pt) * 2009-11-10 2020-08-25 Allegro Pharmaceuticals, Inc. composições e métodos para inibir a adesão celular ou direcionamento dos agentes de diagnóstico ou terapêuticos para os sítios de ligação rgd
PL2603600T3 (pl) 2010-08-13 2019-06-28 Aileron Therapeutics, Inc. Makrocykle peptidomometyczne
JP6106159B2 (ja) 2011-05-09 2017-03-29 アレグロ ファーマシューティカルズ インコーポレイテッドＡｌｌｅｇｒｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｒ−ｇ−システイン酸ペプチドを含む医薬組成物
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
RU2017145921A (ru) 2012-02-15 2019-02-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636066B1 (fr) * 1988-09-02 1991-10-25 Centre Nat Rech Scient Derives de cyclopeptides, utilisables comme inhibiteurs selectifs vis-a-vis de proteases a serine active
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
AU6470590A (en) * 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
IL103252A (en) * 1991-09-30 1997-03-18 Du Pont Merck Pharma CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
FI954556A0 (fi) 1995-09-26
FI954556A (fi) 1995-09-26
NZ263456A (en) 1996-11-26
EP0691987A1 (en) 1996-01-17
AU6415894A (en) 1994-10-24
WO1994022910A1 (en) 1994-10-13
JPH08508498A (ja) 1996-09-10
PL310896A1 (en) 1996-01-08
NO953832D0 (no) 1995-09-28
HU9502832D0 (en) 1995-11-28
CA2159070A1 (en) 1994-10-13
HUT72896A (en) 1996-06-28

Similar Documents

Publication Publication Date Title
NO953832L (no) Sykliske forbindelser som kan anvendes som inhibitorer for blodplateglykoprotein IIb/IIIa
DK36991A (da) Vaevsplasminoaktivator-(t-pa)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmaade til fremstilling deraf, dna-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og vaertsceller transformeret med vektoren
Siigur et al. Biochemical characterization of lebetase, a direct-acting fibrinolytic enzyme from Vipera lebetina snake venom
DK0730590T3 (da) Isoxazolin og isozazol fibrinogenreceptorantagonister
Marshall et al. Coagulant and anticoagulant actions of Australian snake venoms
Suntravat et al. cDNA cloning of a snake venom metalloproteinase from the eastern diamondback rattlesnake (Crotalus adamanteus), and the expression of its disintegrin domain with anti-platelet effects
Korhonen Fibrinolytic and procoagulant activities of Yersinia pestis and Salmonella enterica
ES2120713T3 (es) Compuestos de isoxazolinas utiles como antagonistas de receptores del fibrinogeno.
Collen Thrombolytic therapy
DE59409104D1 (de) Bifunktionelle Urokinasevarianten mit verbesserten fibrinolytischen Eigenschaften und thrombinhemmender Wirkung
ES2337879T3 (es) Procedimiento de dosificacion de la fibrina soluble.
Chu et al. Purification and characterization of a novel fibrinolytic enzyme from Whitmania pigra Whitman
Bisacchi Anticoagulants, antithrombotics, and hemostatics
Moukhametova et al. Properties of the urokinase-type plasminogen activator modified with phenylglyoxal
Bachmann Fibrinolytic agents
Matsushima et al. Activation of fibrinolysis with the protease from Dermatophagoides farinae
Lucena et al. Degradation of extracellular matrix proteins (fibronectin, vitronectin and laminin) by serine-proteinases isolated from Lonomia achelous caterpillar hemolymph
Devi et al. Coagulant and esterase activities of thrombin and Bothrops atrox venom
South et al. Conformational quiescence of ADAMTS‐13 prevents proteolytic promiscuity: reply
Guerrero et al. Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model
Suehiro et al. Enhancing effect of platelets on staphylokinase-mediated clot lysis and plasminogen activation
Islam et al. Longistatin, a novel plasminogen activator from vector ticks, is resistant to plasminogen activator inhibitor-1
Budnik et al. Effects of tranexamic acid, factor XIII, and fibrinogen on clot formation and lysis in the model of hyperfibrinolysis induced by tissue-vs urokinase-type plasminogen activator
MacGillivray et al. Structure of the genes encoding proteins involved in blood clotting
Men'shikov Influence of fibrinolysis system on ADP-and serotonin-induced aggregation of human platelets